Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cenisertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB known ✓ | Q96GD4 | 7/20 | 1.00 |
| ▸ | AURKA known ✓ | O14965 | 2/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 3/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cenisertib SCHEMBL1079632 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL15169719 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL400147 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL1000933 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL30097376 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL15290367 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL1066287 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL1001874 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL10086258 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL12972652 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250146080-A1 | METHODS FOR OVERCOMING TAZEMETOSTAT-RESISTANCE IN CANCER PATIENTS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-05-08 | — | — | US | claimed |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | claimed |
| WO-2024254465-A2 | METHODS FOR PROMOTING EXPANSION OF HUMAN CD34+ CELLS IN VIVO AND FOR PROMOTING NEURAL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| US-20240148688-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | UNIV CALIFORNIA (US) | 2024-05-09 | — | — | US | claimed |
| US-20240150848-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | claimed |
| US-20240108734-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | UNIV CALIFORNIA (US) | 2024-04-04 | — | — | US | claimed |
| EP-4301879-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | Board of Regents, The University of Texas System (US) | 2024-01-10 | — | — | EP | claimed |
| CN-117377492-A | Pharmaceutical composition containing protein kinase inhibitor and medical application thereof | 深圳微芯生物科技股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-116004567-A | Aurora kinase B gene K202 mutation and application thereof | 北京大学 | 2023-04-25 | — | — | CN | claimed |
| WO-2022247844-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PROTEIN KINASE INHIBITOR AND MEDICAL USE THEREOF | 深圳微芯生物科技股份有限公司 | 2022-12-01 | — | — | WO | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022187554-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | claimed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | claimed |
| WO-2022165398-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | WO | claimed |
| US-8546398-B2 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-8030483-B2 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | claimed |
| EP-1824489-B1 | STEREOISOMERICALLY ENRICHED 3-AMINOCARBONYL BICYCLOHEPTENE PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-01-05 | — | — | EP | claimed |
| US-20090176981-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | PIM3, PIM1, PIM2 | AURKB 985/4885AURKA 1223/4885IRAK4 1009/4885 |
| US-20090176981-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, CCNI | AURKB 125/4885AURKA 216/4885IRAK4 4622/4885 |
| US-20240108734-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | FLT3, MCL1, ABL1 | AURKB 310/4885AURKA 212/4885IRAK4 693/4885 |
| US-20240148688-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | ABL1, FLT3, MCL1 | AURKB 349/4885AURKA 449/4885IRAK4 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.